Indo-Bangla Pharmaceuticals (DHA:IBP) Other Long-Term Liabilities: BDT0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT19.70
View Full Analysis

What is Indo-Bangla Pharmaceuticals Other Long-Term Liabilities?

Indo-Bangla Pharmaceuticals DHA:IBP +4.79% 32 Other Long-Term Liabilities is BDT0.00 Mil as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100.

Indo-Bangla Pharmaceuticals's other long-term liabilities for the quarter that ended in . 20 was BDT0.00 Mil.

Indo-Bangla Pharmaceuticals Other Long-Term Liabilities Related Terms

Indo-Bangla Pharmaceuticals Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals Other Long-Term Liabilities Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
Other Long-Term Liabilities

Indo-Bangla Pharmaceuticals Semi-Annual Data
Other Long-Term Liabilities
DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of BDT0.00 Mil mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Other Long-Term Liabilities of BDT0.00 Mil as of . 20. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Indo-Bangla Pharmaceuticals and its competitors.
Is Indo-Bangla Pharmaceuticals' Other Long-Term Liabilities too high?
Indo-Bangla Pharmaceuticals' current Other Long-Term Liabilities is BDT0.00 Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Other Long-Term Liabilities compare to ?
Indo-Bangla Pharmaceuticals' Other Long-Term Liabilities of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Indo-Bangla Pharmaceuticals and its competitors. Indo-Bangla Pharmaceuticals's current Other Long-Term Liabilities is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Other Long-Term Liabilities of BDT0.00 Mil. The current Other Long-Term Liabilities is BDT0.00 Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Other Long-Term Liabilities is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT19.70
Price